Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukaemia.
Kitagawa
S
S
Saito
M
M
Miura
Y
Y
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D017707:Erythrocyte Transfusion; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D010976:Platelet Count; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D002066:Busulfan